Multi-Center Trail Shows Efficacy and Safety of Transurethral Ethanol Ablation of the Prostate (TEAP)
Tuesday, 26 October 2004
BERKELEY, CA (UroToday Inc.) - In recent years, minimally invasive treatments, such as transurethral microwave therapy, needle ablation and laser therapies have provided an increasing degree of success in alleviating lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH).
read more
|
Switching Alpha-Blockers in Non-Responders with LUTS is Not Effective
Thursday, 21 October 2004
BERKELEY, CA (UroToday Inc.) - Availability of alpha-adrenoreceptor blockade has revolutionized the treatment of lower urinary tract symptoms (LUTS) secondary to bladder outlet obstruction.
read more
|
Prostate Specific Antigen Is Related to Benign Prostatic Hyperplasia Not Prostate Cancer Over the Last Five Years
Friday, 15 October 2004
BERKELEY, CA (UroToday Inc.) - Serum prostate specific antigen (PSA) and digital rectal examination are considered the standard of care for the screening of prostate cancer.
read more
|
Prostate Size Shown to Influence Outcome in Men Presenting with Acute Urinary Retention
Thursday, 14 October 2004
BERKELEY, CA (UroToday Inc.) - Historically, the standard management of a man presenting with acute urinary retention (AUR) caused by prostatic obstruction was early prostatectomy, as it was assumed that the patient was presenting late in the natural history of their bladder outlet obstruction.
read more
|
Transurethral Resection of the Prostate Shows Significant Improvement in Quality of Life Indicators Three Months Post-Operatively
Friday, 01 October 2004
BERKELEY, CA (UroToday Inc.) - Benign prostatic hyperplasia (BPH) is the most common benign tumor in men and accounts for bothersome lower urinary tract symptoms in many.
read more
|
PSA No Longer Useful Diagnostic Marker of Prostate Cancer
Monday, 13 September 2004
NEW YORK (Reuters Health) - Dependence on serum levels of prostate specific antigen (PSA) as a marker of cancer has led to overly zealous treatment of men with prostate hyperplasia, investigators at Stanford University report.
read more
|
Treating Voiding Dysfunction with Sacral Nerve Stimulation Can Improve Depression and Quality of Life
Tuesday, 17 August 2004
BERKELEY, CA (UroToday Inc.) - There can be a significant decrease in quality of life and increasing depression with unresolved voiding dysfunction.
read more
|
Sacral Nerve Stimulation for Voiding Dysfunction Improves Quality of Life
Monday, 16 August 2004
NEW YORK (Reuters Health) - Findings from a new study indicate that treating refractory voiding dysfunction with sacral nerve stimulation produces significant improvements in depression and health-related quality of life (HRQOL).
read more
|
International Consultation on Incontinence Questionnaire (ICIQ) Proven to be a Generalizble Outcome Measure for Use in Practice and Research
Thursday, 12 August 2004
BERKELEY, CA (UroToday Inc.) - The International Consultation on Incontinence (ICI) initiated the development of a self-completion questionnaire (ICIQ)in 1998.
read more
|
TURP Safe after Brachytherapy for Prostate Cancer
Friday, 06 August 2004
NEW YORK (Reuters Health) - After an interval of 6 months or longer, transurethral resection of the prostate (TURP) can be safely conducted in men who have undergone brachytherapy as the sole treatment for localized prostate cancer, according to French researchers.
read more
|
BPH & Male LUTS 
